Viswanath Pilla's profile photo

Viswanath Pilla

Mumbai

Journalist at Moneycontrol

Journalist @moneycontrolcom. Tracks pharma/healthcare. Previously @EconomicTimes @livemint @CNBCTV18Live. Views are personal, RTs are not endorsements.

Articles

  • 5 days ago | flipboard.com | Viswanath Pilla

    4 hours agoThailand: Popping-off-a-dom! Rival Indian restaurants clash over turf war leaving three injuredBangkok, Thailand - May 29, 2025 This is the shocking moment rival Indian restaurant owners clashed in a turf war in Thailand. The shopkeepers allegedly began fighting when one accused the other of stealing their customers in the lucrative tourist market of Bangkok. CCTV footage shows the rival chefs hurling plastic stools through the windows and damaging signs during the fracas on May 29.

  • 1 month ago | moneycontrol.com | Viswanath Pilla

    India's drug regulator plans to bring in specialists from the private sector and even abroad in its expert review committees to evaluate complex modern therapies, a marked departure from its long-standing reliance on government-only experts. Central Drugs Standard Control Organisation (CDSCO) chief Dr Rajeev Singh Raghuvanshi described the move as a "very important milestone" necessary to keep pace with innovation.

  • 1 month ago | moneycontrol.com | Viswanath Pilla

    HomeNewsBusinessCompaniesIndian medical device makers prepare for US push, sensing opportunity from China tariffs Trending TopicsRBI Monetary PolicySensex LiveRepo Rate CutIndia GDP GrowthRBI Monetary Policy Highlights Some of the India medical devices companies have started work on regulatory filings and paperwork, to ensure they do not miss out on the opportunity emerging out of this tariff war.

  • 1 month ago | moneycontrol.com | Viswanath Pilla

    Such medications are just one part of a necessary, holistic approach that includes diet, exercise, and addressing significant societal stigma, say experts. April 09, 2025 / 18:34 IST The understanding of obesity in India is shifting, with growing recognition that it's a complex disease requiring medical management, not just a lifestyle issue, experts said during a discussion at the News18 Rising Bharat Summit 2025 in Delhi on Wednesday.

  • 2 months ago | moneycontrol.com | Viswanath Pilla

    Natco Pharma on April 8 said that the launch of its generic version of Roche Pharma's patented drug, Risdiplam, is contingent upon the successful outcome in a patent infringement case. The Hyderabad-based drug maker added that it has decided to price its version of Risdiplam at Rs 15,900. In its exchange filing, the pharma company further added that it intends to offer discount to certain deserving patients through its patient access programme.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers
1K
Tweets
1K
DMs Open
Yes
Viswanath Pilla
Viswanath Pilla @viswanath_pilla
2 Apr 25

RT @moneycontrolcom: #Business | Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? 🏢💊 @viswanath_pilla write…

Viswanath Pilla
Viswanath Pilla @viswanath_pilla
1 Feb 25

patient assistance programs (PAPs) offered by MNC pharma cos free of cost will be fully exempted from duties. PAPs of 37 more medicines, 30 new PAPs will get the exemption. @nsitharamanoffc #BudgetwithET

Viswanath Pilla
Viswanath Pilla @viswanath_pilla
1 Feb 25

Patients suffering from cancer, rare diseases 36 life saving drugs will be fully exempted from basis custom duty, 6 life saving medicines will have concessional duty of 5%. Even their bulk drugs/API will get exemptions and concessional duty. @nsitharamanoffc #BudgetWithET